Please login to the form below

Not currently logged in

F2G appoints chief financial officer

Ralf Schmid brings experience from Nabriva Therapeutics

F2G Ralf SchmidManchester-based F2G Ltd has appointed Ralf Schmid as its new chief financial officer.

Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

He moves to F2G from Nabriva Therapeutics, where he had been a member of the management board since the Austrian biopharmaceutical company's inception in 2006.

Schmid first served as the firm's chief financial officer, before becoming chief executive officer, and most recently held the dual post of chief operating officer and chief financial officer.

 Ian Nicholson, chief executive of F2G, said: “Following our successful $60m financing, I am delighted to welcome Ralf to the F2G team.

“His strong track record in fundraising, M&A transactions and deal structuring will be invaluable as we continue to generate positive data from our clinical trials and position the company for success.”

14th July 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...